Cell Delivery of Therapeutic Nanoparticles
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that are packaged into nanoscale systems for improved delivery. This includes known drugs, proteins, enzymes, and antibodies that have limited clinical efficacy based on delivery, circulating half-lives, or toxicity profiles. The <100 nm nanoscale physical properties afford them a unique biologic potential for biomedical applications. Hence they are attractive systems for treatment of cancer, heart and lung, blood, inflammatory, and infectious diseases. Proposed clinical applications include tissue regeneration, cochlear and retinal implants, cartilage and joint repair, skin regeneration, antimicrobial therapy, correction of metabolic disorders, and targeted drug delivery to diseased sites including the central nervous system. The potential for cell and immune side effects has necessitated new methods for determining formulation toxicities. To realize the potential of nanomedicine from the bench to the patient bedside, our laboratories have embarked on developing cell-based carriage of drug nanoparticles to improve clinical outcomes in infectious and degenerative diseases. The past half decade has seen the development and use of cells of mononuclear phagocyte lineage, including dendritic cells, monocytes, and macrophages, as Trojan horses for carriage of anti-inflammatory and anti-infective medicines. The promise of this new technology and the perils in translating it for clinical use are developed and discussed in this chapter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Photodegradable Hydrogels for Dynamic Tuning of Physical and Chemical Properties
Kloxin, A. M., Kasko, A. M., Salinas, C. N., & Anseth, K. S. (2009) · Science · doi:10.1126/science.1169494 · Cited by 1,748
Liposomes in drug delivery: Progress and limitations
Sharma, A. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00135-x · Cited by 1,253
Winter, P. M., Morawski, A. M., Caruthers, S. D., Fuhrhop, R. W., Zhang, H., Williams, T. A., Allen, J. S., Lacy, E. K., Robertson, J. D., Lanza, G. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000093185.16083.95 · Cited by 696
Direct imaging of single-walled carbon nanotubes in cells
Porter, A. E., Gass, M., Muller, K., Skepper, J. N., Midgley, P. A., & Welland, M. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.347 · Cited by 564
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502
Global analysis of cellular protein translation by pulsed SILAC
Schwanhäusser, B., Gossen, M., Dittmar, G., & Selbach, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800275 · Cited by 356
Cited by
Applications of nanoparticle systems in drug delivery technology
Rizvi, S. A. A., & Saleh, A. M. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.10.012 · Cited by 1,334
Cystic fibrosis lung environment and Pseudomonas aeruginosa infection
Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., & Duan, K. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0339-5 · Cited by 378
Creation of a long-acting nanoformulated dolutegravir
Sillman, B., Bade, A. N., Dash, P. K., Bhargavan, B., Kocher, T., Mathews, S., Su, H., Kanmogne, G. D., Poluektova, L. Y., Gorantla, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02885-x · Cited by 125
Self-citationNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Self-citationTopical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery
Mandal, A., Cholkar, K., Khurana, V., Shah, A., Agrahari, V., Bisht, R., Pal, D., & Mitra, A. K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00128 · Cited by 60
Metadata
- Authors
- McMillan, J., Batrakova, E., & Gendelman, H. E.
- Venue
- Progress in Molecular Biology and Translational Science
- Publisher
- Elsevier
- Published
- 2011
- Volume
- 104
- Pages
- 563-601
- ISSN
- 1877-1173 (ISSN-L)
- OpenAlex
- W166079536
- Cited by
- 138
- References
- 15
- FWCI
- 6.22
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Delivery of Therapeutic Nanoparticles. https://app.cochat.ai/papers/10.1016/b978-0-12-416020-0.00014-0
- The paper
- McMillan, J., Batrakova, E., & Gendelman, H. E. (2011). Cell Delivery of Therapeutic Nanoparticles. Progress in Molecular Biology and Translational Science. https://doi.org/10.1016/b978-0-12-416020-0.00014-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.